StockNews.com initiated coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD – Free Report) in a report issued on Saturday. The firm issued a sell rating on the biopharmaceutical company’s stock.
Galmed Pharmaceuticals Stock Performance
NASDAQ GLMD opened at $3.56 on Friday. The firm’s fifty day moving average is $3.58 and its two-hundred day moving average is $4.07. Galmed Pharmaceuticals has a one year low of $2.73 and a one year high of $10.50. The firm has a market cap of $1.89 million, a PE ratio of -1.48 and a beta of 0.67.
Galmed Pharmaceuticals Company Profile
See Also
- Five stocks we like better than Galmed Pharmaceuticals
- What Is WallStreetBets and What Stocks Are They Targeting?
- Matador Resources Insiders Keep Buying Its Stock, Should You?
- Why Are Stock Sectors Important to Successful Investing?
- Oracle Can Turn the Magnificent 7 Into 8: Here’s Why
- What is Forex and How Does it Work?
- Palantir Stock Is Up 14% on S&P 500 News: Is It Time to Buy?
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.